ArrowMark Colorado Holdings LLC Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR

ArrowMark Colorado Holdings LLC raised its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 8.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 323,166 shares of the company’s stock after buying an additional 24,229 shares during the period. ArrowMark Colorado Holdings LLC owned about 0.56% of Structure Therapeutics worth $9,049,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of GPCR. State of Wyoming purchased a new stake in shares of Structure Therapeutics in the second quarter valued at approximately $28,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Structure Therapeutics by 530.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after acquiring an additional 901 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in shares of Structure Therapeutics by 29.1% in the second quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares in the last quarter. ANTIPODES PARTNERS Ltd increased its stake in Structure Therapeutics by 39.1% during the third quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after purchasing an additional 1,146 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Structure Therapeutics in the second quarter worth $129,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GPCR. JPMorgan Chase & Co. upped their target price on shares of Structure Therapeutics from $65.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, January 22nd. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Structure Therapeutics in a report on Friday, December 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.90.

Structure Therapeutics Stock Down 1.5%

NASDAQ:GPCR opened at $53.75 on Monday. Structure Therapeutics Inc. Sponsored ADR has a fifty-two week low of $13.22 and a fifty-two week high of $94.90. The stock has a market cap of $3.81 billion, a PE ratio of -68.04 and a beta of -1.79. The firm’s fifty day simple moving average is $73.46 and its 200-day simple moving average is $49.72.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities analysts anticipate that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.